Guillermina Barril

Guillermina Barril is presented as a nephrologist based in Madrid and as a coauthor of the book’s major treatment of hepatitis C in hemodialysis. Her significance lies less in a personal narrative than in the clinical authority of the chapter associated with her name: she helps document how hepatitis C moved from a frequent, partly transfusional danger in dialysis units to a preventable nosocomial threat governed chiefly by hygienic practice, surveillance, and evidence-based policy.

Identity and Professional Setting

Guillermina Barril is identified as a nephrologist in the Department of Nephrology at Hospital Universitario de la Princesa in Madrid, Spain. She shares authorship of “Hepatitis C in Hemodialysis: Epidemiology and Prevention of Hepatitis C Virus Transmission” with Michel Jadoul, whose institutional affiliation is the Department of Nephrology at Cliniques Universitaires Saint-Luc and Université catholique de Louvain in Brussels, Belgium. Barril’s placement within a nephrology department is important to the chapter’s perspective: hepatitis C is examined not as an isolated liver infection but as a condition shaped by renal failure, repeated extracorporeal treatment, transfusion history, and the organization of dialysis care.

The chapter is part of a 2012 nephrology volume published by S. Karger AG in Basel. Barril therefore appears within a specialized clinical knowledge network linking Madrid and Brussels, and her named contribution belongs to a period when the central practical question was no longer simply whether dialysis patients were unusually exposed to hepatitis C, but how transmission within dialysis facilities could be recognized, interrupted, and measured.

The Epidemiological Problem She Helps Define

The chapter associated with Barril describes hemodialysis patients as a high-risk group almost immediately after the identification of hepatitis C as the principal cause of non-A, non-B hepatitis in 1989. During the 1990s, both transfusional and nosocomial transmission were relatively frequent. Dialysis patients often required transfusions, and the prevalence of infection was correspondingly high; yet several observations pointed beyond blood products. Infection prevalence correlated strongly with time on dialysis in some studies even after transfusional exposure was taken into account. It was higher among hemodialysis patients than among patients receiving peritoneal dialysis or home hemodialysis, and it remained substantial among patients who had never been transfused.

The epidemiological picture changed as blood-safety measures improved. The risk of post-transfusion hepatitis C, estimated at about 0.5% per blood unit in the 1980s, fell in the United States to approximately 0.0001%, or one case per million blood units, with similarly dramatic improvements in other Western countries. The wider use of erythropoiesis-stimulating agents also reduced reliance on transfusion in the early 1990s. As transfusion ceased to explain the continuing burden, attention shifted toward transmission inside hemodialysis units. Barril’s chapter records this transition as a change in the explanatory center of the disease: the major remaining risk was embedded in clinical routines, equipment, surfaces, and contact between patients and staff.

The subsequent decline in hepatitis C incidence and prevalence in many countries followed the reinforcement of hygienic precautions and, in some settings, isolation strategies. The authors carefully qualify the interpretation of these before-and-after studies, noting that the absence of randomized trials or control groups prevents a firm claim that any particular intervention alone caused the improvement. That caution gives Barril’s contribution a methodological as well as clinical character. The chapter distinguishes an observed temporal improvement from proof of causation, while still identifying the intervention most consistently supported by the evidence: meticulous infection control.

Molecular Evidence and Prevention

From the mid-1990s onward, molecular virology provided decisive confirmation that nosocomial transmission occurred. Studies used phylogenetic analysis of hepatitis C virus isolates collected from patients treated in the same unit and found clusters of closely related isolates, both in individual facilities with high seroconversion rates and in multicenter investigations. Because portions of the viral genome mutate frequently, sequencing could function as a molecular fingerprint, allowing researchers to estimate the probability that isolates came from a common source. When these genetic patterns were combined with epidemiological information from the dialysis unit, they supplied strong evidence for patient-to-patient transmission and indirect evidence about how that transmission took place.

The preventive response described in Barril’s chapter places basic hygiene above architectural or equipment-based separation. The KDIGO workgroup concluded that dedicated dialysis machines for hepatitis C-infected patients were not recommended. It also found no randomized controlled trials supporting ward isolation, while two large prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study and an Italian study, found after multivariable adjustment that isolation did not independently protect other dialysis patients from infection. Isolation was therefore not recommended as a substitute for strict infection-control procedures, although its possible contribution to awareness of transmission risk was acknowledged and a harmful effect was not established.

The operational details are deliberately concrete. Staff should wash their hands with soap or antiseptic handwash and water before and after contact with a patient or equipment at the dialysis station; alcohol-based hand rub is an alternative when hands are not visibly contaminated. Disposable gloves are required when caring for a patient or touching potentially contaminated surfaces, and gloves should be removed before staff leave the station. Single-use items should be discarded after treating one patient. Reusable items must be disinfected or dedicated to one patient, and potentially contaminated station surfaces should be cleaned after every session with an appropriate disinfectant. If a surface is visibly contaminated, a stronger disinfectant is required.

Where dialyser reuse cannot be avoided, reuse for hepatitis C-infected patients may occur only under strict infection-control procedures. The guidelines also address waste management and recommend regular observational audits of infection-control practice as part of performance review in hemodialysis units. In this framework, prevention is not a single barrier but a repeated sequence of hand hygiene, glove discipline, equipment management, environmental cleaning, waste handling, and institutional observation. Barril’s contribution makes the dialysis station itself the central practical landscape of prevention.

Clinical and Public-Health Significance

The wider disease context reinforces why Barril’s subject matters. Hepatitis C infection is a major cause of chronic liver disease worldwide, with an estimated prevalence of about 3% in the global population, while the dialysis-related risk of transmission has been estimated at around 2% per year and varies by country. Strict adherence to hygiene rules can eradicate health-care-related transmission, but occasional nosocomial transmission remains possible. In dialysis populations, current prevalence is influenced substantially by infections acquired before the start of dialysis, including remote infections, whereas current incidence more directly reflects the success or failure of infection-control practice.

The chapter also belongs to a larger diagnostic and therapeutic framework. Active chronic hepatitis C is established by the combination of anti-HCV antibodies and detectable hepatitis C virus RNA; antibody positivity alone cannot distinguish resolved from ongoing infection. Evaluation must consider both hepatic injury and extrahepatic disease, including cryoglobulinemia-associated vasculitis and renal involvement. Liver damage can be assessed by biopsy or noninvasive methods such as FibroScan, which measures liver stiffness and can support yearly follow-up of fibrosis. These distinctions matter in dialysis care because a patient may carry active infection, renal manifestations, or clinically important liver fibrosis even when liver enzyme abnormalities are limited.

The renal consequences extend beyond transmission. Hepatitis C-infected patients have an increased risk of glomerular lesions and chronic kidney disease, including when significant liver disease is absent. A large United States study associated hepatitis C with a higher risk of developing chronic kidney disease stages 3–5, while another comparison found chronic kidney disease in 9.6% of anti-HCV-positive patients versus 5.1% of anti-HCV-negative patients and identified higher baseline viral load as an independent predictor. Hepatitis C is also the major cause of mixed cryoglobulinemia, a systemic vasculitis that may produce purpura, arthralgias, Raynaud phenomena, neuropathy, hypocomplementemia, proteinuria, hematuria, and impaired glomerular filtration. Thus the infection-control problem addressed by Barril sits within a disease system that can damage both liver and kidney.

Outcomes and Lasting Role

The stakes are reflected in survival data. A meta-analysis of seven observational studies involving 11,589 patients receiving long-term dialysis found an independent association between anti-HCV positivity and mortality, with a summary relative risk of 1.34. Liver-related mortality was particularly elevated: the unadjusted relative risk was 5.89 compared with anti-HCV-negative dialysis patients, and hepatocellular carcinoma and cirrhosis were more frequent causes of death among infected patients. In an Australian and New Zealand cohort of 23,046 patients followed for ten years, anti-HCV positivity was independently associated with all-cause mortality, while hepatic failure was a markedly more common cause of death in the infected group. Studies from Japan and the wider Asia-Pacific region likewise linked baseline or dialysis-acquired anti-HCV antibodies with increased mortality.

Barril’s role is therefore best understood through the infrastructure of evidence rather than through biography or plot. Her chapter follows the disease from the high-risk dialysis environment of the 1990s, through the collapse of transfusion risk, to molecular proof of nosocomial spread and the practical supremacy of rigorous hygiene. It also places infection control beside diagnosis, renal pathology, liver assessment, treatment, and survival. The result is a portrait of hepatitis C in hemodialysis as a condition whose outcomes depend not only on viral biology, but also on the repeated conduct of ordinary clinical work.